Variability in Test Interval Is Linked to Glycated Haemoglobin (HbA1c) Trajectory over Time.
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2022
2022
Historique:
received:
03
02
2022
accepted:
20
04
2022
entrez:
26
5
2022
pubmed:
27
5
2022
medline:
28
5
2022
Statut:
epublish
Résumé
We previously showed that the glycated haemoglobin (HbA1c) testing frequency links to diabetes control. Here, we examine the effect of variability in test interval, adjusted for the frequency, on change in HbA1c ( In general, less variability in testing frequency (more consistent monitoring) was associated with better diabetes control. This was most evident with moderately raised baseline HbA1c levels (7.0-9.0% (54-75 mmol/mol)). For example, in those with a starting HbA1c of 7.0-7.5% (54-58 mmol/mol), the lowest SD decile was associated with little change in HbA1c over 5 years, while for those with the highest decile, HbA1c rose by 0.4-0.6% (4-6 mmol/mol; These findings indicate that the consistency of testing interval, not the just number of tests/year, is important in maintaining diabetes control, especially in those with moderately raised HbA1c levels. Systems to improve regularity of HbA1c testing are therefore needed, especially given the impact of COVID-19 on diabetes monitoring.
Identifiants
pubmed: 35615258
doi: 10.1155/2022/7093707
pmc: PMC9126657
doi:
Substances chimiques
Glycated Hemoglobin A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7093707Informations de copyright
Copyright © 2022 Anthony A. Fryer et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Diabetes Care. 2014 Feb;37(2):341-5
pubmed: 24062334
BMJ. 2015 Dec 08;351:h6138
pubmed: 26646052
BMJ Qual Saf. 2021 Sep;30(9):706-714
pubmed: 33542066
Am J Med. 2011 Apr;124(4):342-9
pubmed: 21435425
Health Serv Manage Res. 2022 Aug;35(3):134-145
pubmed: 34148392
Exp Clin Endocrinol Diabetes. 2017 Oct;125(9):625-633
pubmed: 28407667
BMC Fam Pract. 2013 Nov 14;14:170
pubmed: 24225170
Clin Chem. 2012 May;58(5):906-15
pubmed: 22344287
Patient Educ Couns. 2010 Aug;80(2):227-32
pubmed: 20036098
N Engl J Med. 2008 Oct 9;359(15):1577-89
pubmed: 18784090
Dis Manag. 2006 Oct;9(5):277-83
pubmed: 17044761
Pharmgenomics Pers Med. 2014 Jun 19;7:129-36
pubmed: 24971031
Diabetes Care. 2014 Oct;37(10):2731-7
pubmed: 25249670
Fam Pract. 2018 Jan 16;35(1):41-46
pubmed: 28968810
Diabetes Care. 2016 May;39(5):686-93
pubmed: 26861924
N Engl J Med. 2005 Dec 22;353(25):2643-53
pubmed: 16371630
Diabet Med. 2018 Jan;35(1):63-71
pubmed: 29120503
J Endocrinol Invest. 2012 Mar;35(3):269-73
pubmed: 21606668
Diabetes Care. 2021 Jan;44(Suppl 1):S1-S2
pubmed: 33298409
Clin Chem Lab Med. 2018 Dec 19;57(2):296-304
pubmed: 30281512
Diabetes Obes Metab. 2018 Jan;20(1):185-194
pubmed: 28730750
J Clin Pathol. 2013 Jan;66(1):62-72
pubmed: 23015659
J Prim Care Community Health. 2011 Jul 1;2(3):205-8
pubmed: 23804802
J Diabetes Sci Technol. 2009 May 01;3(3):411-7
pubmed: 20144276
J Eval Clin Pract. 2007 Feb;13(1):21-4
pubmed: 17286719
Acta Diabetol. 2015 Jun;52(3):601-9
pubmed: 25539883
J Clin Pathol. 2021 Oct 13;:
pubmed: 34645702
BMJ. 2000 Aug 12;321(7258):405-12
pubmed: 10938048
J Am Board Fam Med. 2013 Nov-Dec;26(6):711-9
pubmed: 24204067
PLoS One. 2016 Apr 06;11(4):e0152428
pubmed: 27050911
Aust J Rural Health. 2016 Dec;24(6):371-377
pubmed: 27086673